IPO Issue Details
Issue Price / Price Band₹460 per share (Fixed Price)
Face Value₹2 Per Share
Lot Size32 Shares per Lot
Total Issue Size1,89,35,819 shares (aggregating up to ₹871.05 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenWed, 10 Dec 2025
Subscription CloseFri, 12 Dec 2025
Anchor AllotmentTue, 09 Dec 2025
Basis of AllotmentMon, 15 Dec 2025
Initiation of RefundsTue, 16 Dec 2025
Credit of Shares to DematTue, 16 Dec 2025
Listing DateWed, 17 Dec 2025
UPI Mandate Deadline2025-12-12
Application & Investment Details
Retail — Min (1 Lots)₹14,720 — 32 shares
Retail — Max (13 Lots)₹191,360 (13 Lots)
HNI — Min (68 Lots)₹10,00,960 — 2,176 shares
EPS (Pre-IPO)₹7.24
EPS (Post-IPO)₹2.84
P/E Ratio (Pre-IPO)63.52x
P/E Ratio (Post-IPO)162.19x
Pre-IPO Promoter Holding9,26,50,799 shares
Post-IPO Promoter Holding10,03,33,516 shares
Fresh Issue Shares76,82,717 shares (aggregating up to ₹353.40 Cr)
Offer for Sale Shares1,12,53,102 shares of ₹2 (aggregating up to ₹517.64 Cr)
About Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, accounting for roughly 10% of the country's total dialysis patient base. Additionally, by Sep 30, it has served 31,046 patients and completed 1,591,377 treatments in India. As of Sep 30, 2025, the company has 5,562 dialysis machines.Nephrocare has formed strategic partnerships with established hospital chains such as Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers.Competitive strengthsIndia’s and Asia’s largest dialysis chain with leadership across our marketsScale coupled with asset-light model driving cost efficiencies and operational excellenceDriving clinical excellence and quality through protocols and advanced technologyOrganic growth augmented by proven track record of acquisitions and integration in India and internationallyPatient-centric leadership and seasoned management team backed by marquee investorsDriving sustainable dialysis leadership with environmental, social and governance measuresTrack record of sustainable growth, profitability and return
Objects of the Issue
Nephrocare Health Services Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Capital expenditure by the Company for opening new dialysis clinics in India
129.11
2
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
136.00
3
General corporate purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
9,26,50,799 shares
Post-IPO Promoter Holding
10,03,33,516 shares